

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
21 October 2004 (21.10.2004)

PCT

(10) International Publication Number
WO 2004/089929 A1

(51) International Patent Classification⁷: **C07D 333/38, 409/12, 417/12, 417/14, A61K 31/381, 31/415, 31/4196, A61P 29/00**

(21) International Application Number: PCT/GB2004/001589

(22) International Filing Date: 13 April 2004 (13.04.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 0308511.5 14 April 2003 (14.04.2003) GB

(71) Applicant (for all designated States except US): ASTEX TECHNOLOGY LIMITED [GB/GB]; 436 Cambridge Science Park, Milton Road, Cambridge CB4 0QA (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **GILL, Adrian, Liam** [GB/GB]; 436 Cambridge Science Park, Milton Road, Cambridge CB4 0QA (GB). **WOODHEAD, Steven** [GB/GB]; 436 Cambridge Science Park, Milton Road,


(74) Agent: **HUTCHINS, Michael, Richard; M.R. Hutchins & Co., 23 Mount Sion, Tunbridge Wells, Kent TN1 1TZ (GB).**

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK,

[Continued on next page]

(54) Title: 5-AMINO-2-CARBONYLTHIOPHENE DERIVATIVES FOR USE AS P38 MAP KINASE INHIBITORS IN THE TREATMENT OF INFLAMMATORY DISEASES



(57) Abstract: The invention provides the use of a compound for the manufacture of a medicament for the prophylaxis or treatment of a disease state or condition mediated by a p38 MAP kinase; the compound being defined by formula (I): wherein: R¹ and R² are the same or different and each is selected from hydrogen, C₁₋₄ hydrocarbyl, halogen and cyano; X is selected from C=O, C=S, C(=O)NH, C(=S)NH, C(=O)O, C(=O)S, C(=S)O and C(=S)S; R³ is selected from aryl and heteroaryl groups each having from 5 to 12 ring members, the aryl and heteroaryl groups each being unsubstituted or substituted by one or more substituent groups R⁷ selected from halogen, hydroxy, trifluoromethyl, cyano, nitro, carboxy, amino, carbocyclic and heterocyclic groups having from 3 to 12 ring members; a group R^a-R^b wherein R^a is a bond, O, CO, X¹C(X²), C(X²)X¹, X¹C(X²)X¹, S, SO, SO₂, NR^c, SO₂NR^c or NR^cSO₂; and R^b is selected from hydrogen, carbocyclic and heterocyclic groups having from 3 to 7 ring members, and a C₁₋₈ hydrocarbyl group optionally substituted by one or more substituents selected from hydroxy, oxo, halogen, cyano, nitro, amino, mono- or di-C₁₋₄ hydrocarbyl amino, carbocyclic and heterocyclic groups having from 3 to 12 ring members and wherein one or more carbon atoms of the C₁₋₈ hydrocarbyl group may optionally be replaced by O, S, SO, SO₂, NR^c, X¹C(X²), C(X²)X¹ or X¹C(X²)X¹; X¹ is O, S or NR^c and X² is =O, =S or =NR^c; R^c is hydrogen or C₁₋₄ hydrocarbyl; R⁴ is a group YR⁵ or a group R⁶; Y is NH, O or S; R⁵ is selected from (a) carbocyclic and heterocyclic groups having from 3 to 12 ring members; and (b) C₁₋₈ hydrocarbyl groups optionally substituted by one or more substituents selected from hydroxy, oxo, halogen, cyano, amino, mono- or di-C₁₋₄ hydrocarbyl amino, and carbocyclic and heterocyclic groups having from 3 to 12 ring members, wherein one or more carbon atoms of the C₁₋₈ hydrocarbyl group may optionally be replaced by O, S, SO, SO₂, NR^c, X¹C(X²), C(X²)X¹ or X¹C(X²)X¹, provided that when Y is 0, a carbon atom adjacent to the group Y is not replaced by O; and R⁶ is a heterocyclic group having from 4 to 12 ring members and containing at least one ring nitrogen atom through which R⁶ is linked to the adjacent carbonyl group; wherein the carbocyclic and heterocyclic groups of substituents R⁵ and R⁶ are each unsubstituted or substituted by one or more substituent groups R⁷ as hereinbefore defined. Also provided are novel compounds, pharmaceutical compositions containing the compounds and methods for their preparation.

WO 2004/089929 A1



TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

- *with international search report*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*